Table 2.
Feature
|
n = 38
|
First-line treatment | |
Temozolomide/capecitabine | 35 (92.1) |
CAPOX | 1 (2.6) |
Cisplatin/etoposide | 1 (2.6) |
Interferon alpha | 1 (2.6) |
First-line cycles | |
Median (IQR) | 9 (6-22.75) |
Duration of first-line treatment, days | |
Median (IQR) | 331 (133.25-606) |
Second-line treatment | |
Yes | 14 (36.8) |
No | 24 (63.2) |
Second-line regimen, n = 14 | |
Capecitabine | 4 (28.6) |
CAPOX | 3 (21.4) |
TEMCAP | 3 (21.4) |
Cisplatin/etoposide | 1 (7.1) |
Dacarbazine (DTIC) | 1 (7.1) |
GEMOX | 1 (7.1) |
Temozolomide | 1 (7.1) |
IQR: Interquartile range; TEMCAP: Temozolomide and capecitabine regimen; CAPOX: capecitabine/oxaliplatin; GEMOX: gemcitabine/oxaliplatin.